Study to Evaluate the Effect of BYDUREON on 24-hour Glucose Control in Metformin Treated Patients With Type 2 Diabetes.

NCT02288273 · Completed

Last updated 2026-05-28

This clinical trial tests the effect of the medication BYDUREON on blood sugar levels over a full 24-hour period in adults with type 2 diabetes who are already taking metformin.

Status Completed The study has finished.

Phase Phase 4 Monitors a drug already on the market.

Type Interventional (clinical trial)

Design Randomized, triple-blind treatment study

Participants 239 people

Who can join Ages 18–75 · all sexes

Timeline Started 2014-12 · est. completion 2015-08

Where 29 sites · United States

What this study is testing ClinicalTrials.gov NCT02288273 ↗

Description as written by the study sponsor.

A Randomized, Double-blind, Parallel-group Study to Evaluate the Effect of Bydureon Compared with Placebo on 24-hour Glucose Control in Metformin-treated Patients with Type 2 Diabetes.

Treatments tested

Bydureon also known as exenatide Drug

Once weekly injection of 2mg bydureon (extended release exenatide) for 10 weeks.
Placebo Drug

Placebo

Main thing measured	Change in 24-hour Mean Weighted Glucose
Sponsor	AstraZeneca
Conditions studied	Type 2 Diabetes
GLP-1 drugs	exenatide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT02288273 ↗